Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data

Basit Öğe Kaydı
dc.authorid0000-0003-1237-8281
dc.authorid0000-0001-9636-4113
dc.contributor.authorBirtaş Ateşoğlu, Elif
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorUzay, Ant
dc.contributor.authorÖzcan, Muhit
dc.contributor.authorÖzkalemkaş, Fahir
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKalyon, Hakan
dc.contributor.authorAkay, Olga Meltem
dc.contributor.authorFerhanoğlu, Burhan
dc.date.accessioned2024-01-18T12:41:46Z
dc.date.available2024-01-18T12:41:46Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractGlofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patients with relapsed/refractory (R/R) B-cell lymphoma. However, the real-world data of patients of all ages with no strict selection criteria are still lacking. Herein, this retrospective study aimed to evaluate the outcomes of diffuse large B-cell lymphoma (DLBCL) patients who received glofitamab via compassionate use in Turkey. Forty-three patients from 20 centers who received at least one dose of the treatment were included in this study. The median age was 54 years. The median number of previous therapies was 4, and 23 patients were refractory to first-line treatment. Twenty patients had previously undergone autologous stem cell transplantation. The median follow-up time was 5.7 months. In efficacy-evaluable patients, 21% and 16% of them achieved complete response and partial response, respectively. The median response duration was 6.3 months. The median progression-free survival (PFS) and overall survival (OS) was 3.3 and 8.8 months, respectively. None of the treatment-responsive patients progressed during the study period, and their estimated 1-year PFS and OS rate was 83%. The most frequently reported toxicity was hematological toxicity. Sixteen patients survived, while 27 died at the time of the analysis. The most common cause of death was disease progression. One patient died of cytokine release syndrome during the first cycle after receiving the first dose of glofitamab. Meanwhile, two patients died due to glofitamab-related febrile neutropenia. This is the largest real-world study on the effectiveness and toxicity of glofitamab treatment in R/R DLBCL patients. The median OS of 9 months seems promising in this heavily pretreated group. The toxicity related mortality rates were the primary concerns in this study.
dc.identifier.citationBirtaş Ateşoğlu, E., Gülbaş, Z., Uzay, A., Özcan, M., Özkalemkaş, F. ve Dal, M. S. (2023). Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data. Hematological Oncology, 41(4), 663-673. https://dx.doi.org/10.1002/hon.3174
dc.identifier.doi10.1002/hon.3174
dc.identifier.endpage673
dc.identifier.issn0278-0232
dc.identifier.issn1099-1069
dc.identifier.issue4
dc.identifier.pmid37211991
dc.identifier.scopus2-s2.0-85159808449
dc.identifier.scopusqualityQ1
dc.identifier.startpage663
dc.identifier.urihttps://dx.doi.org/10.1002/hon.3174
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12173
dc.identifier.volume41
dc.identifier.wos000991717000001en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorBeköz, Hüseyin
dc.institutionauthorSevindik, Ömür Gökmen
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofHematological Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-NoDerivs 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBispecific Antibodies
dc.subjectGlofitamab
dc.subjectRelapsed/Refractory Diffuse Large B?Cell Lymphoma
dc.titleGlofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Bekoz-Huseyin-2023.pdf
Boyut:
798.87 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu